Structured evidence table for Maca Menopausal Symptoms Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Maca Menopausal Symptoms Randomized Trial | It drives many physiological, emotional, and mental shifts that occur during this transition, including vasomotor symptoms, bone loss, alterations in body composition, changes in mood and cognition, and increased cardiometabolic risk []. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
| Maca Menopausal Symptoms Randomized Trial | 29 30 31 32 33 Historically, this rise with the transition from the reproductive to menopausal stage of life has been interpreted primarily as a compensatory response to declining ovarian function and reduced negative feedback from the ovaries []. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
| Maca Menopausal Symptoms Randomized Trial | 34 35 36 37 34 38 39 40 Another point of consideration is the evidence accumulating for FSH’s actions beyond the ovary. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
| Maca Menopausal Symptoms Randomized Trial | 1 2 3 4 Over the past two decades, perimenopause and menopause have emerged as prominent topics in medical and public discourse. | 3 | Minich Deanna (2026) | Is Follicle-Stimulating Hormone (FSH) Misnamed? Rethinking Its Role in Menopause as a Systemic Regulator of Bone, Brain, Metabolism, and Aging |
| Maca Menopausal Symptoms Randomized Trial | Depression can impair desire, arousal, orgasm and satisfaction before pharmacotherapy, while serotonergic antidepressants may further disturb these domains during treatment, complicating causal attribution and underscoring the need to distinguish depression-related sexual dysfunction from antidepressant-associated sexual dysfunction (AISD). | 4 | Liu X (2026) | Plant-derived bioactives in depression-related and antidepressant-associated sexual dysfunction: a narrative review. |
| Maca Menopausal Symptoms Randomized Trial | We conducted a narrative review based on targeted searches of PubMed/MEDLINE, Web of Science and Scopus through June 2026, synthesizing mechanistic and clinical evidence for selected candidates by phenotype specificity to separate direct AISD studies from adjacent clinical or preclinical evidence and mechanistic plausibility. | 4 | Liu X (2026) | Plant-derived bioactives in depression-related and antidepressant-associated sexual dysfunction: a narrative review. |
| Maca Menopausal Symptoms Randomized Trial | Saffron provides the most coherent AISD-specific signal, supported by small randomized trials in women and men with fluoxetine-associated sexual dysfunction. | 4 | Liu X (2026) | Plant-derived bioactives in depression-related and antidepressant-associated sexual dysfunction: a narrative review. |
| Maca Menopausal Symptoms Randomized Trial | Sexual dysfunction related to depression and antidepressant treatment is clinically important yet underrecognized, affecting adherence, intimate functioning and quality of life. | 4 | Liu X (2026) | Plant-derived bioactives in depression-related and antidepressant-associated sexual dysfunction: a narrative review. |
Source documents